Medicare Enrolled
Dr. Bradley Switzer, MD
Internal Medicine · Worrester, MA
Practice pattern: Mixed Practice
— Diverse clinical practice across multiple procedure types
Low-engagement
Very High
DATA COVERAGE
Data in 4 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating.
This page presents federal public records about Dr. Switzer from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Dr. Switzer?
Request a correction or review of any data shown here. Provider portal →
What this data tells you about Dr. Switzer
Dr. Bradley Switzer is an internal medicine specialist in Worrester, MA, with 19 years of NPI registration. Based on federal Medicare data, Dr. Switzer performed 39,037 Medicare services across 1,257 unique beneficiaries.
Between the years covered by Open Payments, Dr. Switzer received a total of $4,092 from 31 pharmaceutical and/or device companies across 200 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common in internal medicine. Most payments are for meals and travel — low-value interactions common across virtually all practicing physicians. Patients may wish to discuss these relationships with their provider.
The Data Coverage level for Dr. Switzer is Very High — reflecting how much public federal data is available about this provider. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.
✓ 19 years in practice
▲ Top 0% volume in MA
$4,092 industry payments
Medicare Practice Summary
Medicare Utilization ↗39,037
Medicare services
Top 0% in MA for internal medicine
1,257
Unique beneficiaries
$13
Avg. Medicare payment
Medicare patients only (65+ / disabled) · How to read this →
~2,055 Medicare services per year of practice
Top procedures by volume
Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.
| Procedure | Volume | Avg. paid | Avg. submitted |
|---|---|---|---|
| Iron infusion (Feraheme) An injection of ferumoxytol used to treat iron deficiency anemia in patients not on dialysis. |
12,750 | $0 | $1 |
| Iron sucrose injection (Venofer) An injection of iron sucrose used to replenish iron levels in the body. |
7,500 | $0 | $1 |
| Pembrolizumab injection (Keytruda) | 6,400 | $43 | $97 |
| Anti-nausea injection (fosaprepitant) An injection of fosaprepitant, a medication used to prevent nausea and vomiting. |
2,850 | $0 | $4 |
| Abatacept infusion (Orencia) An injection of abatacept administered under the direct supervision of a physician. This code is used for Medicare when the drug is not self-administered. |
2,025 | $34 | $107 |
| Rituximab-pvvr biosimilar injection, 10 mg An injection of rituximab-pvvr, a biosimilar medication, administered in a 10 mg dose. |
1,930 | $22 | $138 |
| Infliximab-dyyb biosimilar injection, 10 mg An injection of infliximab-dyyb, a biosimilar medication, administered in a 10 mg dose. |
1,000 | $15 | $182 |
| Dexamethasone injection (steroid) An injection of dexamethasone sodium phosphate, a corticosteroid medication, administered in a dose of 1 milligram. |
960 | $0 | $1 |
| Anti-nausea injection (Aloxi/palonosetron) | 630 | $1 | $50 |
| Epoetin alfa injection (Retacrit) for anemia An injection of a biosimilar form of epoetin alfa used for non-end-stage renal disease purposes. The dose administered is 1000 units. |
480 | $6 | $19 |
| Intravenous injection of additional new drug or substance Administration of an additional new medication or substance directly into a vein. |
349 | $13 | $63 |
| Office visit, established patient (20-29 min) An office visit for an existing patient lasting between 20 and 29 minutes. The visit involves medical evaluation and management of the patient's condition. |
248 | $66 | $211 |
| Zoledronic acid injection, 1 mg An injection of zoledronic acid administered at a dose of 1 mg. |
217 | $6 | $209 |
| Office visit, established patient (30-39 min) A follow-up office visit for an existing patient lasting between 30 and 39 minutes. The visit involves medical evaluation and management of the patient's condition. |
201 | $94 | $313 |
| Intravenous infusion, 1 hour or less Administration of medication or fluid directly into a vein for therapeutic, preventive, or diagnostic purposes. The procedure lasts one hour or less. |
200 | $52 | $215 |
| Intravenous chemotherapy infusion, 1 hour or less Administration of chemotherapy medication directly into a vein. The procedure takes one hour or less to complete. |
183 | $108 | $400 |
| Carboplatin chemotherapy injection, 50 mg Administration of a 50 mg dose of carboplatin, a chemotherapy medication, via injection. |
174 | $2 | $37 |
| Office visit, established patient, complex (40-54 min) An office or outpatient visit for an existing patient lasting between 40 and 54 minutes. This level of service is determined by the total time spent on the date of the encounter. |
138 | $137 | $440 |
| Diphenhydramine injection, up to 50 mg An injection of diphenhydramine hydrochloride, an antihistamine medication, administered in a dose of up to 50 milligrams. |
95 | $1 | $3 |
| Methylprednisolone injection, up to 125 mg An injection of methylprednisolone sodium succinate, a corticosteroid medication, with a dosage of up to 125 mg. |
80 | $4 | $11 |
| Additional hour of intravenous infusion This code represents each additional hour of intravenous infusion beyond the initial hour for therapy, prevention, or diagnosis. |
79 | $16 | $62 |
| Unclassified drug A medication that does not fit into standard HCPCS or CPT classification categories. |
73 | $1 | $9 |
| Intravenous infusion of new drug or substance, 1 hour or less This procedure involves administering a new medication or substance directly into a vein through an existing access site. The infusion is completed within one hour or less. |
64 | $54 | $198 |
| Comprehensive metabolic blood panel A blood test that measures a group of chemicals, including glucose, electrolytes, and kidney and liver function markers. |
57 | $10 | $41 |
| Complete blood count (CBC) with differential An automated laboratory test that measures the levels of red blood cells, white blood cells, and platelets in the blood, including a breakdown of the different types of white blood cells. |
56 | $8 | $30 |
| Drug injection, under skin or into muscle A procedure involving the administration of a medication or substance via injection into the subcutaneous tissue or muscle. |
54 | $11 | $67 |
| Additional hour of intravenous chemotherapy This code represents the administration of chemotherapy medication into a vein for each additional hour beyond the initial period. |
52 | $23 | $84 |
| Additional sequential IV infusion, 1 hour or less This code represents an additional intravenous infusion administered sequentially to a primary infusion. It covers the administration time of one hour or less. |
50 | $24 | $90 |
| Intravenous drug injection A procedure involving the administration of a medication or substance directly into a vein. |
32 | $30 | $155 |
| Intravenous push injection of new drug or substance A healthcare provider injects a new medication or substance directly into a vein using a push technique. |
28 | $46 | $171 |
| Initial hospital admission, moderate complexity Initial hospital inpatient or observation care for a new patient involving moderate-level medical decision making, with at least 55 minutes total time on the date of the encounter. |
19 | $104 | $354 |
| New patient office visit (45-59 min) An initial office visit for a new patient lasting between 45 and 59 minutes. This code covers the total time spent by the physician or qualified healthcare professional on the date of the encounter. |
17 | $131 | $455 |
| New patient office visit, complex (60-74 min) | 16 | $178 | $551 |
| Injection, hydrocortisone sodium succinate, up to 100 mg | 16 | $12 | $31 |
| Initial hospital admission, high complexity Initial hospital inpatient or observation care for a new patient involving high-level medical decision making, with at least 75 minutes total time on the date of the encounter. |
14 | $139 | $521 |
How to read this data: This reflects Medicare patients only (typically 65+). Payment amounts are what Medicare paid the provider, not your out-of-pocket cost. A higher procedure volume generally indicates more experience with that procedure.
39.3% high complexity
58.5% medium
2.1% routine
Industry Payment Transparency
Open Payments through 2024 ↗$4,092
Total received (2018-2024)
Avg $585/year across 7 years
Top 18% in MA for internal medicine
A higher payment rank reflects disclosed industry relationships (consulting, research, speaking) common among subspecialists — not wrongdoing.
31
Companies
200
Individual payments
All payments are legal and publicly reported · Not evidence of wrongdoing · How to interpret →
Payment profile
Industry payments classified by relationship type. Not all payments are equal — research and consulting reflect different relationships than speaking programs or meals.
Meals & Travel
Food, beverages, travel, and lodging — typically low-value
$4,000 (97.8%)
Speaking / Promotional
Speaker programs, honoraria, and industry-sponsored educational events
$92 (2.2%)
Payment trend by year
Annual totals from pharmaceutical and medical device companies.
2024
$58
2023
$253
2022
$59
2021
$34
2020
$610
2019
$1,805
2018
$1,273
Payments by company (2024)
Consulting
Speaking
Meals & Travel
Research
AstraZeneca Pharmaceuticals LP
$30
ABBVIE INC.
$28
Top 3 companies account for 100.0% of 2024 payments
All-time payments by company (2018-2024) ›
E.R. Squibb & Sons, L.L.C.
$631
Merck Sharp & Dohme Corporation
$453
Celgene Corporation
$425
Bayer HealthCare Pharmaceuticals Inc.
$279
AstraZeneca Pharmaceuticals LP
$261
Incyte Corporation
$254
Genentech USA, Inc.
$247
EISAI INC.
$163
Pharmacyclics LLC, An AbbVie Company
$156
Janssen Biotech, Inc.
$149
Daiichi Sankyo Inc.
$122
PFIZER INC.
$119
Myriad Genetic Laboratories, Inc.
$116
Lilly USA, LLC
$107
Boehringer Ingelheim Pharmaceuticals, Inc.
$66
Seattle Genetics, Inc.
$62
Stemline Therapeutics Inc.
$59
Seagen Inc.
$51
Takeda Pharmaceuticals U.S.A., Inc.
$50
Amgen Inc.
$48
Eisai Inc.
$48
Otsuka America Pharmaceutical, Inc.
$38
Novartis Pharmaceuticals Corporation
$33
ABBVIE INC.
$28
CTI BioPharma Corp.
$25
Karyopharm Therapeutics Inc.
$21
Clovis Oncology, Inc.
$20
Exelixis Inc.
$18
Ipsen Biopharmaceuticals, Inc
$15
Gilead Sciences, Inc.
$12
Astellas Pharma US Inc
$12
Top 3 companies account for 36.9% of all-time payments
Associated products mentioned in payments ›
ADCETRIS · Abraxane · Alecensa · Aliqopa · CYRAMZA · Cabometyx · Cristacath · DARZALEX · EMPLICITI · EPANOVA · EPKINLY · ERBITUX · Erleada · FASLODEX · GILOTRIF · Halaven · Herceptin · IBRANCE · IMBRUVICA · IMFINZI · INJECTAFER · INREBIC · INVEGA TRINZA · Idhifa · Imbruvica · Inrebic · JAKAFI · KANJINTI · KEYTRUDA · KISQALI · LYNPARZA · Lenvima · MVASI · MYRISK · NINLARO · Nexavar · ONUREG · OPDIVO · Orserdu · PADCEV · PEMAZYRE · Perjeta · Pomalyst · Revlimid · Rubraca · SOMATULINE DEPOT · SPRYCEL · Stivarga · TAGRISSO · VENCLEXTA · VERZENIO · VOTRIENT · Vonjo · XALKORI · XPOVIO · XTANDI · Xofigo
Should you be concerned? Payments from pharmaceutical and device companies are legal and common — 57% of U.S. physicians receive at least one. They often reflect legitimate consulting, research, or education. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →
Most payments (98%) are for meals and travel — low-value interactions that are common across virtually all practicing physicians.
Data Sources
| Provider Registry | ✓ NPPES | Weekly updates |
| Medicare Enrollment | ✓ PECOS | Monthly updates |
| Practice Data | ✓ Medicare Util. | Annual (CY lag) |
| Industry Payments | ✓ Open Payments | CY 2024 |
| Disciplinary History | — Not public | N/A |
This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This reflects how much public data is available about a provider. How we calculate this →
Summary
Dr. Switzer is a mixed practice specialist, with above-average Medicare volume (top 0% in MA), with low-engagement industry engagement in the top 18% of MA peers, with 19 years of NPI registration.
This summary is auto-generated from federal data, describing data availability and patterns. Read our methodology →
Frequently Asked Questions
Is Dr. Switzer experienced with iron infusion (feraheme)?
Based on Medicare claims data, Dr. Switzer performed 12,750 iron infusion (feraheme) services. Research suggests that higher procedure volume is often associated with better outcomes, particularly for complex procedures. Note that Medicare data only captures patients aged 65 and older, so the total practice volume across all patients is likely higher.
Does Dr. Switzer receive payments from pharmaceutical companies?
Yes. Dr. Switzer received a total of $4,092 from 31 companies across 200 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common among physicians — 57% of all U.S. physicians receive at least one industry payment. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
How do Dr. Switzer's costs compare to other internal medicine physicians in Worrester?
Dr. Switzer's average Medicare payment per service is $13. Note that these figures represent what Medicare pays, not your out-of-pocket cost, which depends on your specific insurance plan and deductible. Procedure-level data above shows both what was submitted and what Medicare paid for each service type.
What does Data Coverage mean?
Data Coverage (currently Very High for Dr. Switzer) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating a long track record of practice, Medicare participation, and industry disclosure. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Each data source has its own update cycle. Provider registry data (NPPES) is updated weekly. Medicare enrollment (PECOS) is updated monthly. Medicare practice data has a ~2 year lag — the most recent available is typically 2 years prior. Industry payment data (Open Payments) is published annually, usually in June, covering the prior calendar year. We display the data date prominently on each section so you always know how current it is. See our data freshness policy →
Explore related providers
Same specialty & city
Internal Medicine Physicians in Worrester
Browse internal medicine physicians in Worrester ranked by procedure volume and transparency data.
Highest volume
Top Internal Medicine Physicians in MA
Internal medicine physicians ranked by total Medicare services performed statewide.
Industry payments
Pharma Payments to Internal Medicine Physicians in MA
Which MA internal medicine physicians receive the most from drug and device companies.
By company
E.R. Squibb & Sons, L.L.C. Payments to Doctors
See all physicians who received payments from E.R. Squibb & Sons, L.L.C.
By company
Merck Sharp & Dohme Corporation Payments to Doctors
See all physicians who received payments from Merck Sharp & Dohme Corporation.
By company
Celgene Corporation Payments to Doctors
See all physicians who received payments from Celgene Corporation.
About this page
All data on this page is sourced verbatim from public federal records published by the U.S. Centers for Medicare & Medicaid Services (CMS): NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.
This page is not medical advice, an endorsement, a recommendation, or a quality rating. Data Coverage reflects data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.
Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology